Skip to main content
SpringerLink
Log in

Neue Arzneimittel

  • Chapter
Arzneiverordnungs-Report 2003

Zusammenfassung

Die Zahl neuer Arzneimittel ist seit 1986 mit wenigen Unterbrechungen kontinuierlich angestiegen und hat 1997 mit 41 neuen Wirkstoffen einen einstweiligen Höhepunkt erreicht (Abbildung 2.1). Seitdem geht in Deutschland die Markteinführung neuartiger Arzneimittel zurück. Im Jahr 2002 wurden nur noch 28 neue Wirkstoffe in die Therapie eingeführt. Eine ähnliche Entwicklung zeichnet sich weltweit ab (Taylor 2003). Die Arzneimittel mit neuen Wirkstoffen werden seit 1987 im Arzneiverordnungs-Report mit den Bewertungen von Fricke und Klaus (siehe Fricke 2000) tabellarisch dargestellt. Seit drei Jahren verfassen wir zusätzlich kurze Charakterisierungen der einzelnen neuen Wirkstoffe und geben Empfehlungen zu ihrer Anwendung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Alexander C.L., Miller S.J., Abel S.R. (2002): Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann. Pharmacother. 36: 504–511.

    Article  PubMed  CAS  Google Scholar 

  • Ally R., Schürmann D., Kreisel W., Carosi G., Aguirrebengoa K., Dupont B. et al. and the Esophageal Candidiasis Study Group (2001): A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33: 1447–1454.

    Article  PubMed  CAS  Google Scholar 

  • Arato M., O’Connor R., Meltzer H.Y. and the ZEUS Study Group (2002): A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int. Clin. Psychopharmacol. 17: 207–215.

    Article  PubMed  CAS  Google Scholar 

  • Arzneimittelkommission der deutschen Apotheker (2002): Rote-Hand-Brief: Parecoxib (Dynastat®). Pharm. Ztg. 147: 4188.

    Google Scholar 

  • Arzneimittelkommission der deutschen Apotheker (2003): Vertriebseinstellung von Nefadar. Pharm. Ztg. 148: 625–000.

    Google Scholar 

  • Basset-Seguin N., Ibbotson S., Emtestam L., Tarstedt M., Morton C, Maroti M. et al. (2001): Photodynamic therapy using metvix is as efficacious as cryotherapy in BCC, with better cosmetic results. J. Eur. Acad. Dermatol. Venereol. 15(Suppl. 2): 226–227.

    Google Scholar 

  • Bernard G.R. (2003): Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit. Care Med. 31(Suppl.): S85–S93.

    Article  PubMed  CAS  Google Scholar 

  • Bernard G.R., Vincent J.-L., Laterre P.-R, LaRosa S.P., Dhainaut J.-R, Lopez-Rodriguez A. et al. (2001): Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344: 699–709.

    Article  PubMed  CAS  Google Scholar 

  • Bochelen D., Rudin M., Sauter A. (1999): Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J. Pharmacol. Exp. Ther. 288: 653–659.

    PubMed  CAS  Google Scholar 

  • Bresnihan B., Alvaro-Gracia J.M., Cobby M., Doherty M., Domlijan Z., Emery P. et al. (1998): Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis. Rheum. 41: 2196–2204.

    Article  PubMed  CAS  Google Scholar 

  • Buchan P., Keywood C, Wade A., Ward C. (2002): Clinical pharmacokinetics of frovatriptan. Headache. 42(Suppl. 2): S54–S62.

    Article  PubMed  Google Scholar 

  • Carmichael J., Popiela T., Radstone D., Falk S., Borner M., Oza A. et al. (2002): Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20: 3617–3627.

    Article  PubMed  CAS  Google Scholar 

  • Casaburi R., Mahler D.A., Jones P.W., Wanner A., San P.G., ZuWallack R.L. et al. (2002): A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19: 217–224.

    Article  PubMed  CAS  Google Scholar 

  • Channick R.N., Simonneau G., Sitbon O., Robbins I.M., Frost A.,Tapson V.F. et al. (2001): Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–1123.

    Article  PubMed  CAS  Google Scholar 

  • Cheer S.M., Goa K.L. (2001): Parecoxib (parecoxib sodium). Drugs 61:1133–1141.

    Article  PubMed  CAS  Google Scholar 

  • Cohen S., Hurd E., Cush J., Schiff M., Weinblatt M.E., Moreland L.W. et al. (2002): Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46: 614–624.

    Article  PubMed  CAS  Google Scholar 

  • Curran M., Noble S. (2001): Valganciclovir. Drugs 61: 1145–1150.

    Article  PubMed  CAS  Google Scholar 

  • Davidson B.L., Geerts W.H., Lensing A.W.A. (2002a): Low-dose heparin for severe sepsis. N. Engl. J. Med. 347: 1036–1037.

    Article  PubMed  Google Scholar 

  • Davidson M.H., McGarry T., Bettis R., Melani L., Lipka L.J., LeBeaut A.P. et al. (2002b): Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40: 2125–2134.

    Article  PubMed  CAS  Google Scholar 

  • Donat F., Duret J.P., Santoni A., Cariou R., Necciari J., Magnani H., de Greef R. (2002): The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin. Pharmacokinet. 41(Suppl. 2): 1–9.

    Article  PubMed  CAS  Google Scholar 

  • Donohue J.E, van Noord J.A., Bateman E.D., Langley S.J., Lee A., Witek T.J. Jr. et al. (2002): A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122: 47–55.

    Article  PubMed  CAS  Google Scholar 

  • Douillard J.-Y., Hoff P.M., Skillings J.R., Eisenberg P., Davidson N., Harper P. et al. (2002): Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 20: 3605–3616.

    Article  PubMed  CAS  Google Scholar 

  • Duvic M., Martin A.G., Kim Y., Olsen E., Wood G.S., Crowley C.A., Yocum R.C. (2001a): Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch. Dermatol. 137: 581–593.

    PubMed  CAS  Google Scholar 

  • Duvic M., Hymes K., Heald P., Breneman D., Martin A.G., Myskowski P. et al. (2001b): Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J. Clin. Oncol. 19: 2456–2471.

    PubMed  CAS  Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2001): Fosean, European Public Assessment Report (EPAR), 24 October 2001.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2002a): Tamiflu, European Public Assessment Report (EPAR), 20 June 2002.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2002b): Dynastat, European Public Assessment Report (EPAR), 22 March 2002.

    Google Scholar 

  • European Agency for the Evaluation of Medicinal Products (EMEA) (2002c): Vfend, European Public Assessment Report (EPAR), 19 March 2002.

    Google Scholar 

  • Food and Drug Administration/Center for Drug Evaluation and Research (2001): Geodon (Ziprasidone HCl) Capsules. Medical Review, February 2001. http://www.fda.gov/cder/foi/nda/2001/20-825_Geodan.htm

  • Food and Drug Administration/Center for Drug Evaluation and Research (2002a): Caspofungin. FDA Advisory Committee Meeting Background Jan. 10, 2001 [cited Jan 3]. Available from: http://www.fda.gov/ohrms/dockets/ac/cder01.htm#Antiviral.

  • Food and Drug Administration/Center for Drug Evaluation and Research (2002b): Elidel (Pimecrolimus) Cream. Medical Review, May 2002. http://www.fda.gov/cder/foi/nda/2001/21-302_Elidel.htm

  • Fowler C.J., Janson U., Johnson R.M., Wahlstrom G., Stenstrom A., Norstrom K, Tiger G. (1999): Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Arch. Biochem. Biophys. 362: 191–196.

    Article  PubMed  CAS  Google Scholar 

  • Fricke U. (2000): Arzneimittelinnovationen-Neue Wirkstoffe: 1978-1999. Eine Bestandsaufnahme. In: Klauber J., Schröder H., Selke G.W. (Hrsg.): Innovation im Arzneimittelmarkt, Springer-Verlag, Berlin-Heidelberg-New York, pp. 85–97.

    Chapter  Google Scholar 

  • Fricke U. (2002): Neue Arzneimittel-Ein Überblick. Therapiesymposium 2002. Arzneimittelkommission der deutschen Ärzteschaft, Bad Nauheim.

    Google Scholar 

  • Fricke U, Klaus W. (1994): Neue Arzneimittel 1993. Fortschritte für die Arzneimitteltherapie? Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, pp. 16–28.

    Google Scholar 

  • Fried M.W. (2003): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C. N. Engl. J. Med. 348: 260.

    Article  Google Scholar 

  • Fried M.W., Shiffman M.L., Reddy K.R., Smith C, Marinos G., Goncalez EL. et al. (2002): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975–982.

    Article  PubMed  CAS  Google Scholar 

  • Friedman M.A., Ignoffo R.J. (1980): A review of the United States clinical experience of the fluoropyrimidine, ftorafur (NSC-148958). Cancer Treat. Rev. 7: 205–213.

    Article  PubMed  CAS  Google Scholar 

  • Fuchs RE, Barry A.L., Brown S.D. (2001): In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 north American medical centers. Antimicrob. Agents Chemother. 45: 1915–1918.

    Article  PubMed  CAS  Google Scholar 

  • Fujisawa Healthcare, Inc. (2000): Tacrolimus ointment (0.03% and 0.1%) in atopic dermatitis. Briefing document: NDA 50-777. Washington DC: US Food and Drug Administration.

    Google Scholar 

  • Gagné C, Gaudet D., Bruckert E. for the Ezetimibe Study Group (2002): Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105: 2469–2475.

    Article  PubMed  Google Scholar 

  • Gardner S.E, Franks A.M. (2003): Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Ann. Pharmacother. 37: 99–105.

    Article  PubMed  CAS  Google Scholar 

  • Gunasekara N.S., Spencer C.M., Keating G.M. (2002): Ziprasidone. A review of its use in schizophrenia and schizoaffective disorder. Drugs 62: 1271–1251.

    Article  Google Scholar 

  • Hayden EG., Atmar R.L., Schilling M., Johnson C., Poretz D., Paar D. et al. and the Oseltamivir Study Group (1999): Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 341: 1336–1343.

    Article  PubMed  CAS  Google Scholar 

  • Heintges T., Erhardt A., Sagir A., Häussinger D. (2002): Kombinationstherapie der chronischen Hepatitis C. Dtsch. Ärztebl. 99: A1239–A1241.

    Google Scholar 

  • Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.-W. et al. for the Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002): Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347: 408–415.

    Article  PubMed  CAS  Google Scholar 

  • Hirsch S.R., Kissling W., Bauml J., Power A., O’Connor R. (2002): A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J. Clin. Psychiatry 63: 516–523.

    Article  PubMed  CAS  Google Scholar 

  • Hotchkiss R.S., Karl I.E.-(2003): The pathophysiology and treatment of sepsis. N. Engl. J.Med. 348: 138–150.

    Article  PubMed  CAS  Google Scholar 

  • IMS World Review (2002): 2002 World Pharma Sales Growth: Slower, but still healthy, http://www.ims-global.com. 28. Februar 2003.

  • Jiang Y., Genant H.K., Watt I., Cobby M., Bresnihan B., Aitchison R., McCabe D. (2000): A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologie progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43: 1001–1009.

    Article  PubMed  CAS  Google Scholar 

  • Karbowski A., Schwitalle M., Eckart A. (1998): Oxaprozin versus Diclofenac retard zur Behandlung der aktivierten Arthrose. Z. Rheumatol. 57: 108–113.

    Article  PubMed  CAS  Google Scholar 

  • Karim A., Laurent A., Slater M.E., Kuss M.E., Qian J., Crosby-Sessoms S.L., Hubbard R.C. (2001): A pharmaeokinetie study of intramuscular (IM) parecoxib sodium in normal subjects. J. Clin. Pharmacol. 41: 1111–1119.

    Article  PubMed  CAS  Google Scholar 

  • Kawai S., Nishida S., Kato M., Furumaya Y., Okamoto R., Koshino T., Mizushima Y. (1998): Comparison of cyclooxygenase-1 and-2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur. J. Pharmacol. 347: 87–94.

    Article  PubMed  CAS  Google Scholar 

  • Keam S.J., Goa K.L. (2002): Fondaparinux sodium. Drugs 62: 1673–1685.

    Article  PubMed  CAS  Google Scholar 

  • Kubler A.C., Haase T., Staff C, Kahle B., Rheinwald M., Mühling J. (1999): Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck. Lasers Surg. Med. 25: 60–68.

    Article  PubMed  Google Scholar 

  • Lapane K.L., Spooner J.J., Mucha L., Straus W.L. (2001): Effect of nonsteroidal antiinflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care. J. Am. Geriatr. Soc. 49: 577–584.

    Article  PubMed  CAS  Google Scholar 

  • Lissauer H. (1865): Zwei Fälle von Leucaemie. Berliner Klin. Wschr. 2: 403–404.

    Google Scholar 

  • Luger T., Van Leent E.J.M., Graeber M., Hedgecock S., Thurston M., Kandra A. et al. (2001): SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Brit. J. Dermatol. 144: 788–794.

    Article  CAS  Google Scholar 

  • Makarowski W., Weaver A., Rubin B., Caldwell J., McMahon EG., Noveck R.J. et al. (1996): The efficacy, tolerability, and safety of 1200mg/d of Oxaprozin and 1500 mg/d of nabumetone in the treatment of patients with Osteoarthritis of the knee. Clin. Ther. 18: 114–124.

    Article  PubMed  CAS  Google Scholar 

  • Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R. et al. and the International Hepatitis Interventional Therapy Group (2001): Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965.

    Article  PubMed  CAS  Google Scholar 

  • Martin D.R, Sierra-Madero J., Walmsley S., Wolitz R.A., Macey K., Georgiou P. et al. for the Valganciclovir Study Group (2002): A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N. Engl. J. Med. 346: 1119–1126.

    Article  PubMed  CAS  Google Scholar 

  • McClellan K., Perry CM. (2001): Oseltamivir. A review of its use in influenza. Drugs 61: 263–283.

    Article  PubMed  CAS  Google Scholar 

  • Miller L.G. (1992): Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug. Clin. Pharm. 11:591–603.

    PubMed  CAS  Google Scholar 

  • Netland P.A., Landry T., Sullivan E.K., Andrew R., Silver L., Weiner A. et al. for the Travoprost Study Group (2001): Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132:472–484.

    Article  PubMed  CAS  Google Scholar 

  • Nghiem P., Pearson G., Langley R.G. (2002): Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J. Am Acad. Dermatol. 46: 228–241.

    Article  PubMed  Google Scholar 

  • Nicholson K.G., Aoki F.Y., Osterhaus A.D.M.E., Trottier S.,Carewicz O., Mercier C.H. et al. on behalf of the Neuraminidase Inhibitor Flu Treatment Investigator Group (2000): Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 355: 1845–1850.

    Article  PubMed  CAS  Google Scholar 

  • Noecker R.S., Dirks M.S., Choplin N.T., Bernstein P., Batoosingh A.L., Whitcup S.M. (2003): A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am. J. Ophthalmol. 135: 55–63.

    Article  PubMed  CAS  Google Scholar 

  • Oparil S., Williams D., Chrysant S.G., Marbury T.C., Neutel J. (2001): Comparative efficacy of olmesartan, losartan, valsarían, and irbesartan in the control of essential hypertension. J. Clin. Hypertens. 3: 283–291,318.

    Article  CAS  Google Scholar 

  • Pazdur R., Lassere Y., Rhodes V., Ajani J.A., Sugarman S.M., Patt Y.Z. et al. (1994): Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol. 12: 2296–2300.

    PubMed  CAS  Google Scholar 

  • Peters P.H., Gravenstein S., Norwood P., De Bock V., Van Couter A., Gibbens M. et al. (2001): Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J. Am. Geriatr. Soc. 49: 1025–1031.

    Article  PubMed  Google Scholar 

  • Rakov N.E. (2003): Peginterferon alfa-2a plus ribavirin for chronic hepatitis C. N. Engl. J. Med. 348: 259–260.

    Article  PubMed  Google Scholar 

  • Ratner RH., Lim J.C., Georges G.C. and the Ebastine Study Group (2000): Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis. J. Allergy Clin. Immunol. 105: 1101–1107.

    Article  PubMed  CAS  Google Scholar 

  • Reitamo S., Rustin M., Ruzicka T., Cambazard E, Kalimo K.,Friedman RS. et al. for the European Tacrolimus Ointment Study Group (2002a): Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J. Allergy Clin. Immunol. 109: 547–555.

    Article  PubMed  CAS  Google Scholar 

  • Reitamo S., VanLeent E.J.M., Ho V., Harper J., Ruzicka T., Kalimo K. et al. for the European/Canadian Tacrolimus Ointment Study Group (2002b): Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J. Allergy Clin. Immunol. 109: 539–546.

    Article  PubMed  CAS  Google Scholar 

  • Riendeau D., Percival M.D., Brideau C, Charleson S., Dubé D., Ethier D. et al. (2001): Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296: 558–566.

    PubMed  CAS  Google Scholar 

  • Rubin L.J., Badesch D. B., Barst R.J., Galié N., Black CM., Keogh A. et al. for the Bosentan Randomized Trial of Endothelin Antagonist Therapy Study Group (2002): Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346: 896–903.

    Article  PubMed  CAS  Google Scholar 

  • Ruzicka T., Bieber T., Schöpf E., Rubins A., Dobozy A., Bos J.D. et al. for the European Tacrolimus Multicenter Atopic Dermatitis Study Group (1997): A short-term trial of tacrolimus ointment for atopic dermatitis. N. Engl. J. Med. 337: 816–821.

    Article  PubMed  CAS  Google Scholar 

  • Ryan R., Geraud G., Goldstein J., Cady R., Keywood C. (2002): Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 42(Suppl. 2): S84–S92.

    Article  PubMed  Google Scholar 

  • Sacks EM. (2002): Low-density lipoprotein lowering therapy: An analysis of the options. J. Am. Coll. Cardiol. 40: 2135–2138.

    Article  PubMed  Google Scholar 

  • Sandrini G., Farkkila M., Burgess G., Forster E., Haughie S. (2002): Eletriptan vs Sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 59: 1210–1217.

    Article  PubMed  CAS  Google Scholar 

  • Schooley R.T., Ruane P., Myers R.A., Beall G., Lampiris H., Berger D. et al. for the Study 902 Team (2002): Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 16:1257–1263.

    Article  PubMed  CAS  Google Scholar 

  • Sherwood M., Brandt J. (2001): Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv. Ophthalmol. 45(Suppl 4): S361–S368.

    Article  PubMed  Google Scholar 

  • Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E. et al. (2001): United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 19: 3852–3860.

    PubMed  CAS  Google Scholar 

  • Soter N.A., Fleischer A. B., Webster G.F., Monroe E., Lawrence L, and the Tacrolimus Ointment Study Group (2001) Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, Safety. J. Am. Acad. Dermatol. 44: S39–S46.

    Article  PubMed  CAS  Google Scholar 

  • Staszewski S., Gallant J., Pozniak A.L., Suleiman A.H., De Jesus E., Koenig E. et al. for the 903 Study Team (2002): Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combination with lamivudione (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. XIV International AIDS Conference, Barcelona July 7-12,2002.

    Google Scholar 

  • Stein E. (2001): Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur. Heart J Suppl. 3(Suppl. E): E11–E16.

    Article  CAS  Google Scholar 

  • Stedman C.A.M., Barclay M.L. (2000): Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment. Pharmacol. Ther. 14: 963–978.

    Article  PubMed  CAS  Google Scholar 

  • Sudhop T., von Bergmann K. (2002): Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 62: 2333–2347.

    Article  PubMed  CAS  Google Scholar 

  • Sun H.D., Ma L., Hu X.C., Zhang T.D. (1992): Treatment of acute promyelocytic leukemia by Ailing-I therapy with use of syndrome differentiation of traditional Chinese medicine. Chin. J. Comb. Trad. Chin. Med. West. Med. 12:170–171.

    Google Scholar 

  • Szeimies R.M., Karrer S., Radakovic-Fijan S., Tanew A., Calzavara-Pinton P.G., Zane C. et al. (2002): Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J. Am. Acad. Dermatol. 47: 258–262.

    Article  PubMed  CAS  Google Scholar 

  • Talpur R., Ward S., Apisarnthanarax N., Breuer-Mcham J., Duvic M. (2002): Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 47: 672–684.

    Article  PubMed  Google Scholar 

  • Tang J., Li S., White P.E, Chen X., Wender R.H., Quon R. et al. (2002): Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology 96:1305–1309.

    Article  PubMed  CAS  Google Scholar 

  • Taylor D. (2003): Fewer new drugs from the pharmaceutical industry. Brit. Med. J. 326: 408–409.

    Article  PubMed  Google Scholar 

  • The European Agency for the Evaluation of Medicinal Products (EMEA) (2001): Fosean (Temoporfin). CPMP/2738/01.

    Google Scholar 

  • Todd P.A., Brogden R.N. (1986): Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 32: 291–312.

    Article  PubMed  CAS  Google Scholar 

  • Treanor J.J., Hayden F.G., Vrooman P.S., Barbarash R., Bettis R., Riff D. et al. for the US Oral Neuraminidase Study Group (2000): Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 283: 1016–1024.

    Article  PubMed  CAS  Google Scholar 

  • Turpie A.G.G., Bauer K.A., Eriksson B.I., Lassen M.R. (2002): Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med. 162:1833–1840.

    Article  PubMed  CAS  Google Scholar 

  • Vetter N., Cambronero-Hernandez E., Rohlf J., Simon S., Carides A., Oliveria T., Isaacs R. for the Protocol 020 Study Group (2002): A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin. Ther. 24:1770–1785.

    Article  PubMed  CAS  Google Scholar 

  • Vincken W, van Noord J.A., Greefhorst A.P., Bantje T.A., Kesten S., Korducki L., Cornelissen P.J. for the Dutch/Belgian Tiotropium Study Group (2002): Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur. Respir. J. 19: 209–216.

    Article  PubMed  CAS  Google Scholar 

  • Warren H.S., Suffredini A.E, Eichacker P.Q., Munford R.S. (2002): Risks and benefits of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347:1027–1030.

    Article  PubMed  Google Scholar 

  • Weaver A., Rubin B., Caldwell J., McMahon F.G., Lee D., Makarowski W. et al. (1995): Comparison of the efficacy and safety of Oxaprozin and nabumetone in the JL treatment of patients with Osteoarthritis of the knee. Clin. Ther. 17: 735–745.

    Article  PubMed  CAS  Google Scholar 

  • Wellington K., Jarvis B. (2002): Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs. 62: 817–840.

    Article  PubMed  CAS  Google Scholar 

  • Welliver R., Monto A.S., Carewicz O., Schatteman E., Hassman M., Hedrick J. et al. (2001): Effectiveness of oseltamivir in preventing influenza in household contacts. JAMA. 285: 748–754.

    Article  PubMed  CAS  Google Scholar 

  • WHO Collaborating Centre for Drug Statistics Methodology (2003): ATC-Index mit DDD 2003. WHO-Zentrum für die Erarbeitung der Methodik der Arzneimittelstatistik, Oslo, Norwegen.

    Google Scholar 

  • Wiseman L.R., Faulds D. (1996): Ebastine. A review of its pharmacological properties and clinical efficacy in the treatment of allergic disorders. Drugs. 51: 260–277.

    Article  PubMed  CAS  Google Scholar 

  • Yellin A.E., Hassett J.M., Fernandez A., Geib J., Adeyi B., Woods G.L., Teppler H. for the 004 Intra-abdominal Infection Study Group (2002): Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int. J. Antimicrob. Agents 20: 165–173.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Uwe Fricke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universitat Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Germany

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Fricke, U., Schwabe, U. (2004). Neue Arzneimittel. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2003. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18512-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18512-0_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-40188-9

  • Online ISBN: 978-3-642-18512-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation